Rare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Pharmaceuticals, a division of Canada’s Novelion. Aegerion holds US ...
Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS ...
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan ...
DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback